Alnylam Pharmaceuticals, Inc.

Healthcare · Biotechnology

Overall research band Weak

Quality Mixed

Valuation Very weak

Balance sheet Mixed

Market confirmation Not available

One-minute company read

What this report can tell you now

What the company does

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery, development, and commercialization of RNA interference (RNAi) therapeutics. The company offers approved therapies including ONPATTRO for polyneuropathy in hereditary transthyretin-mediated amyloidosis, GIVLAARI for acute hepatic porphyria, and OXLUMO for primary hyperoxaluria type 1. Alnylam's pipeline targets a range of conditions such as inherited genetic disorders, cardio-metabolic diseases, hepatic infectious diseases, and CNS and ocular disorders, with investigational therapies like givosiran, patisiran, cemdisiran, ALN-AAT02, ALN-HBV02, zilebesiran, ALN-HSD, fitusiran, inclisiran, and vutrisiran in various stages of development. The company generates revenue through the sale of its approved therapies and through strategic alliances and licensing agreements with pharmaceutical partners including Regeneron, Sanofi Genzyme, Novartis, Vir Biotechnology, Dicerna Pharmaceuticals, Ionis Pharmaceuticals, and PeptiDream.

The current research profile is Industrial Company. This is a starting point for investigation, not a forecast or recommendation.

Strongest visible signal

No single strength should be treated as decisive without reviewing the underlying evidence and data status.

What to investigate next

Read the latest filing or company update, check the period behind the metrics, and investigate the dimension with the weakest band above.

Before you draw a conclusion

Read the latest filing or company update.
Check the financial period behind each metric.
Investigate the weakest score band and any missing evidence.

Headline fundamentals

A small set of signals worth checking

ROIC120.7%Model input; read with the evidence status and period context.

Operating margin13.5%Model input; read with the evidence status and period context.

Revenue CAGR · 4 years44.8%Model input; read with the evidence status and period context.

FCF margin12.5%Model input; read with the evidence status and period context.

Go deeper when you need to

Compare the right companies, understand what changed, and monitor the evidence.

Peer contextCompare companies using the appropriate economic neighborhood.

Evidence detailSee exact inputs, source context, and model-aware metrics.

HistoryReview score and research changes over time.

MonitoringKeep the questions, risks, and changes that matter in view.

The public report remains useful on its own. Premium adds depth, history, comparison, and monitoring.